Status:

COMPLETED

Confocal Laser Endomicroscopy Nodule Localization by Robotic Bronchoscopy

Lead Sponsor:

Johnson & Johnson Enterprise Innovation Inc.

Conditions:

Lung Neoplasms

Eligibility:

All Genders

22+ years

Phase:

NA

Brief Summary

This study is designed to evaluate the safety and feasibility of real-time needle-based confocal laser endomicroscopy (nCLE) in improving diagnostic accuracy of robotic-assisted bronchoscopy (RANB) bi...

Detailed Description

Robotic-assisted navigational bronchoscopy (RANB) improves accuracy of lesion localization and diagnostic yield of the peripheral pulmonary nodule (PPN) biopsy compared to conventional flexible bronch...

Eligibility Criteria

Inclusion

  • Age ≥ 22 years at signing of informed consent form (ICF).
  • Undergoing standard-of-care RANB for a solid lung nodule, which is considered to be at intermediate- to high-risk for malignancy as determined by the investigator per the institution's standard of care.
  • ICF signed before any study procedures are initiated.

Exclusion

  • Medical contraindication to bronchoscopy under general anesthesia, or lack of physical fitness to undergo bronchoscopy under general anesthesia or to follow the study processes, as assessed by the investigator.
  • Presence of uncorrectable bleeding disorders, or anticoagulation/anti-platelet aggregation therapy that cannot be withheld for an appropriate interval prior to the procedure, as defined per the institution's standard of care.
  • Medical devices interfering with electro-magnetic navigation, including but not limited to pacemakers.
  • Subjects who have a target lesion that shows endobronchial involvement on chest CT.
  • Participation in any other clinical trial within 30 days of enrollment, that would interfere with this study.
  • Known hypersensitivity to fluorescein sodium or any other ingredients in the fluorescein product.
  • Planned surgical resection at the time of bronchoscopy
  • Female subjects who are pregnant or nursing at the time of the procedure.

Key Trial Info

Start Date :

January 20 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 6 2024

Estimated Enrollment :

53 Patients enrolled

Trial Details

Trial ID

NCT05231278

Start Date

January 20 2022

End Date

September 6 2024

Last Update

April 25 2025

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

John Muir Health

Concord, California, United States, 94520

2

Clinical Research Associates of Central PA

Altoona, Pennsylvania, United States, 16602

3

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

4

Fox Chase Cancer Center of the American Oncologic Hospital, Inc.

Philadelphia, Pennsylvania, United States, 19129